The Weight-Loss Revolution People Didn't Want
Despite effective weight-loss drugs like Ozempic, many remain overweight due to psychological resistance and societal glorification of obesity, with the real barrier being cultural rather than medical.
Background
- The article discusses GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) — originally diabetes medications that cause significant weight loss by mimicking a hormone that regulates appetite and digestion.
- Demand has exploded, making Novo Nordisk and Eli Lilly two of the world's most valuable companies and sparking shortages, insurance debates, and cultural controversy.
- The "revolution people didn't want": widespread ambivalence — health benefits are real, but critics raise concerns about side effects, high cost, pressure to medicate rather than address systemic causes of obesity, and the stigma of taking a "cheat" drug.